Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM
A legfontosabb adatok
- Ki végzi
- Royal North Shore Hospital
- Hol
- Ausztrália1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Visszavonva
- Kezdés
- 2024. okt. 3.
- Befejezés
- 2024. okt. 3.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
- A regiszteradat frissítve
- 2024. november 18.
- Miért állt le
- no resources to run the trial
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Patients undergoing definitive external beam radiotherapy at Northern Sydney Cancer Centre
- Patients histologically proven prostate adenocarcinoma
- PSA obtained within 3 months prior to enrolment
- Pelvic lymph nodes are included for treatment for patients at stage T1c-T3b with Gleason 8-10 or prostate-specific antigen (PSA) > 20 ng/ml or pelvic lymph node positivity on conventional imaging or prostate-specific membrane antigen (PSMA) scans
- Patient must be able to have gold fiducial markers placed in the prostate
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Ability to understand and the willingness to sign a written informed consent document
- Prostate dimension that allows leaf span with tracking margin of ±8mm
Ki nem vehet részt
- Patients with artificial Hip(s), lumbar spinal surgical rods or other large metallic pelvic implants
- Patient's dimensions >40cm as measured at the level of the prostate
- Patients with overlapping implanted gold fiducials in x-ray imaging
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Assessing the feasibility of implementing real-time multi-leaf collimator (MLC) tracking to account for the relative motion of the moving prostate tumour target and the static pelvic nodal target for high-risk prostate cancer patients. The capability of tracking for the relative motion of multiple targets will ensure that all the treatment targets receive correct dose as prescribed by the doctor and minimise side effects to the critical organs.
A vizsgálat 2 csoportja
- Stage 1: Optimise nodal treatment marginA vizsgált kezelés
During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
Kezelés: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
- Stage 2: Use treatment marginA vizsgált kezelés
During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
Kezelés: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase I Feasibility Study of Accounting for Relative Motion of Multiple Targets in Prostate Cancer Radiotherapy Using Realtime Multi-leaf Collimator Adaptation and Kilovoltage (kV) Intrafraction Monitoring
- A regiszteradat frissítve
- 2024. november 18.